Navigation Links
Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on GenSpera, Inc.
Date:6/2/2009

NEW YORK, June 2 /PRNewswire/ -- Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO(R)) on GenSpera, Inc., a closely held company. The full 56-page report can be found at www.crystalra.com.

GenSpera, Inc. ("GenSpera" or "the Company") is a development-stage biotechnology company focused on the discovery and development of prodrug cancer therapies. A prodrug is an inactive precursor of a drug that is converted into its active form at a targeted site. The Company has developed a novel approach to chemotherapy using a prodrug to deliver a potent, cell-killing agent to tumor sites while avoiding toxicity in healthy, non-cancerous cells. GenSpera's prodrugs target cancer cells in one of two ways: (1) by targeting tumor-associated blood vessels; or (2) by targeting tumors directly.

The Company's lead prodrug candidate, G-202, is designed to attack existing tumor vasculature, potentially debilitating the tumor's nutrient supply and causing cancer regression without affecting normal tissues within the body. In preclinical evaluation, G-202 demonstrated anti-tumor effects on the growth of breast, renal, bladder, and prostate cancers. Due to G-202's specific mechanism of action as well as its solid preclinical breast cancer data, GenSpera has selected breast cancer as the initial clinical focus, and intends to submit an Investigational New Drug (IND) application for G-202 during the second quarter 2009. Further, to prepare for clinical trials, the Company has formulated a Phase I clinical plan for G-202 together with investigators at Johns Hopkins' Sidney Kimmel Comprehensive Cancer Center and the University of Wisconsin Comprehensive Cancer Center, locations where GenSpera plans to conduct the Phase I trial.

The Company's technology can also be used to attack cancer cells directly by targeting the prodrug to enzymes believed to be found solely at a tumor location. G-115, GenSpera's primary candidate using this approach, targets prostate-specific antigen (PSA), a protein produced by the cells of the prostate gland that is used by physicians as a "tumor marker" to detect the presence of prostate cancer. The Company is also working to identify additional candidates in this program.

Based in San Antonio, Texas, GenSpera aims to begin trading on the Over-the-Counter Bulletin Board (OTC.BB) in the third quarter 2009.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC is an independent research firm that provides institutional-quality, fee-based research to small and mid-cap companies. Crystal Research Associates' unique and novel product, the Executive Informational Overview(R) (EIO(R)), is free of investment ratings, target prices, and forward-looking financial models. The EIO(R) presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO(R) details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City, Delray Beach, Montreal, and Toronto. Crystal Research Associates has been compensated by the Company in cash of thirty-eight thousand five hundred U.S. dollars and fifty thousand Options/Warrants for its services in creating this report, for updates, and for printing costs.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements including, limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including forms filed with the SEC.

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.


'/>"/>
SOURCE Crystal Research Associates, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Recombinant Human Renin - Crystallographic Grade
2. 3-D photonic crystals will revolutionize telecommunications
3. Researchers outline structure of largest nonvirus particle ever crystallized
4. DNA technique yields 3-D crystalline organization of nanoparticles
5. DiObex and Camurus Sign License Agreement for the Development of DIO-901 in FluidCrystal(R) Extended Release Technology
6. CRELUX and ProQinase establish joint crystal-grade kinase protein and structures platform
7. NC State breakthrough results in super-hard nanocrystalline iron that can take the heat
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd.
9. Silicon photonic crystals key to optical cloaking, researchers say
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
11. New Dual Wavelength X-ray Diffractometer From Oxford Diffraction, Now a Part of Varian, Inc., Allows Increased Throughput for Challenging Single Crystal Analyses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , ... August 15, 2017 , ... Kapstone Medical ... 10 years of successes helping medical technology companies and inventors develop and safeguard their ... renowned full-service national engineering firm with a portfolio of clients in the United States ...
(Date:8/15/2017)... (PRWEB) , ... August 15, 2017 , ... ... new family of 6” modular downlights designed to stay tightly sealed and perform ... areas where damp and wet location listings just aren't enough, such as: hospitals; ...
(Date:8/14/2017)... ... 14, 2017 , ... Every year, millions of dollars are ... community have recently come together to address this antibody crisis and develop standards ... , The team at Thermo Fisher Scientific has arranged for an ...
(Date:8/11/2017)... ... ... A staple in the community for more than 60 years, Bill Miller ... a new digital marketing strategy and updated logo. , As part of the initiative ... the South Texas Blood & Tissue Center for the month of August. , ...
Breaking Biology Technology:
(Date:4/18/2017)... Inc., a global expert in SoC-based imaging and computing solutions, has ... features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® ... be showcased during the upcoming Medtec Japan at Tokyo Big Sight ... Las Vegas Convention Center April 24-27. ... Click here for an image of the ...
(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
Breaking Biology News(10 mins):